A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma-Reference-Cited by-同舟云学术

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma

Published:2012-10 Issue:10 Volume:23 Page:2687-2695
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Morschhauser F.,Recher C.,Milpied N.,Gressin R.,Salles G.,Brice P.,Vey N.,Haioun C.,Colombat P.,Rossi J.F.,Deconinck E.,Lazreg F.,Bergougnoux L.,Delsol G.,Attal M.

Funder

Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/10/2687/13788510/mds202.pdf

Reference57 articles.

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project;Blood,1997

2. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project;Armitage;J Clin Oncol,1998

3. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005